Researchers described a mucin-responsive nanomedicine that disassembles into unimers in vivo to improve solid-tumor penetration and therapeutic delivery. In mouse cancer models, the approach increased penetration through extracellular barriers and improved antitumor efficacy compared with strategies that rely on conventional nanoparticle behavior under mucin-rich conditions. The work focuses on overcoming a common delivery bottleneck in solid tumors: dense mucus-like components and tumor microenvironment interactions that prevent macromolecules and particles from reaching malignant cells. The study’s mechanism centers on stimulus-driven disassembly to change how the drug behaves in tissue. The findings are preclinical, but they add to a growing set of mechanism-driven delivery concepts that prioritize penetration and spatial activity rather than accumulation alone.